%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-06-03T12:30:10Z
2024-03-28T23:42:16-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T23:42:16-07:00
application/pdf
Heather
2004-493.july
uuid:91fcd919-1dd2-11b2-0a00-870927fd5800
uuid:91fcd91b-1dd2-11b2-0a00-6a0000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
123 0 obj
[127 0 R]
endobj
124 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.03641 Tw 10 0 0 10 54 734.8264 Tm
[(studies are necessary to further evaluate the safety and ef)17.7 (fec-)]TJ
0.02499 Tw 0 -1.2 TD
[(tiveness of RA)-220.2 (drugs in this population.)]TJ
0.1348 Tw 1.2 -1.2 Td
(Maintaining mobility and activity among the elderly is)Tj
0.3345 Tw -1.2 -1.2 Td
(clinically important for both physical and psychosocial)Tj
0.0327 Tw T*
(health. Compounded comorbidity often results in less func-)Tj
0.06731 Tw T*
(tional reserve, such that a particular medical condition that)Tj
0.1062 Tw T*
(has minimal impact on a younger patient is likely to have)Tj
0.0374 Tw T*
(greater health related consequences in an elderly individual)Tj
0.0631 Tw T*
[(with an underlying chronic disease. )17.8 (Thus, optimizing med-)]TJ
0.02499 Tw T*
[(ical therapy for the elderly with active RA)-220.2 (is imperative.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.0845 Tw 8 0 0 8 54 592.8264 Tm
(The authors thank Marc Lachs for his assistance in the data management)Tj
0.02499 Tw 0 -1.25 TD
[(for this study)64.8 (.)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 54 558.8264 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 548.8264 Tm
[(1.)-875.1 (Proust JJ. Immunity and ageing. In: Evans JG, )17.7 (W)39.8 (illiams )17.7 (TF)79.7 (, Beattie)]TJ
1.675 -1.25 Td
[(BL, Michel J-P)110.7 (, )17.7 (W)39.8 (ilcock GK, editors. Oxford textbook of geriatric)]TJ
T*
[(medicine. 2nd ed. New )36.8 (Y)99.8 (ork: Oxford University Press; 2000:68-79.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Fleischmann RM, Baumgartner SW)91.7 (, )17.7 (T)35 (indall EA, et al. Response to)]TJ
1.675 -1.25 Td
(etanercept \(Enbrel\) in elderly patients with rheumatoid arthritis: a)Tj
T*
(retrospective analysis of clinical trial results. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:691-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Dudley NJ, Bowling )54.8 (A, Bond M, et al. )54.8 (Age- and sex-related bias in)]TJ
1.675 -1.25 Td
[(the management of heart disease in a district general hospital. )54.8 (Age)]TJ
0 Tc T*
(Aging 2002;31:37-42.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Hajjar I, Miller K, Hirth )17.7 (V)128.9 (.)-0.1 ( )54.8 (Age-related bias in the management of)]TJ
1.675 -1.25 Td
[(hypertension: a national survey of physicians\325)-201.1 (opinions on )]TJ
T*
[(hypertension in elderly adults. J Gerontol )54.8 (A)-220.1 (Biol Sci Med Sci)]TJ
0 Tc 0 Tw T*
(2002;57:M487-91.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Langer C. Elderly patients with lung cancer: biases and evidence.)]TJ
1.675 -1.25 Td
[(Curr )17.7 (T)35 (reat Options Oncol 2002;3:85-102.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Muss HB. Factors used to select adjuvant therapy of breast cancer)]TJ
1.675 -1.25 Td
(in the United States: an overview of age, race, and socioeconomic)Tj
T*
(status. J Natl Cancer Inst Monogr 2001;30:52-5.)Tj
31.325 45.921 Td
[(7.)-875.1 (Klippel JH, Dieppe P)91.7 (A. Rheumatology)64.9 (. 2nd ed. Bethesda, MD:)]TJ
0 Tc 1.675 -1.25 Td
(Mosby; 1998.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (American College of Rheumatology)64.8 (. Rheumatoid arthritis fact)]TJ
1.675 -1.25 Td
[(sheet. )54.8 (Atlanta: )54.8 (American College of Rheumatology; 2003. )54.8 (A)73.9 (vailable)]TJ
T*
[(from: www)64.8 (.rheumatology)64.8 (.or)17.7 (g/patients/factsheet/RA.html. )54.8 (Accessed)]TJ
0 Tc T*
[(March 1)36.9 (1, 2005.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Arthritis Foundation. Disease center \321 rheumatoid arthritis.)]TJ
1.675 -1.25 Td
[(A)73.9 (vailable from: www)64.8 (.arthritis.or)17.7 (g/conditions/DiseaseCenter/ra.asp.)]TJ
T*
[(Accessed March 1)36.8 (1, 2005.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Kaipiainen-Seppanen O, )54.8 (Aho K, Isomaki J, Laakso M. Shift in the)]TJ
2.175 -1.25 Td
(incidence of rheumatoid arthritis toward elderly patients in Finland)Tj
0 Tc T*
(during 1975-1990. Clin Exp Rheumatol 1996;14:537-42.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Linos )54.8 (A, )17.7 (W)79.9 (orthington JW)91.7 (, O\325Fallon )17.7 (WM, Kurland L)91.7 (T)74 (. )17.7 (The )]TJ
2.1381 -1.25 Td
[(epidemiology of rheumatoid arthritis in Rochester)39.7 (, Minnesota: a)]TJ
T*
[(study of incidence, prevalence, and mortality)64.8 (. )54.8 (Am J Epidemiol)]TJ
0 Tw T*
[(1980;1)36.8 (1)36.8 (1:87-98.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (US Bureau of the Census. )54.8 (Administration on aging: aging into the)]TJ
2.175 -1.25 Td
[(21st century)64.8 (. )54.8 (A)73.9 (vailable from:)]TJ
0 Tw T*
[(www)64.9 (.aoa.gov/prof/statistics/future_growth/future_growth.asp )]TJ
0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Pincus )17.7 (T)74 (, Callahan LF)79.7 (. )17.7 (T)69.9 (aking mortality in rheumatoid arthritis )]TJ
2.175 -1.25 Td
(seriously \321 predictive markers, socioeconomic status and )Tj
T*
[(comorbidity)64.8 (. J Rheumatol 1986;13:841-5.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Pincus )17.7 (T)74 (, Brooks RH, Callahan LF)79.7 (. Prediction of long-term )]TJ
2.175 -1.25 Td
(mortality in patients with rheumatoid arthritis according to simple)Tj
T*
[(questionnaire and joint count measures. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1994;120:26-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (W)79.9 (atson D, Rhodes )17.7 (T)74 (,)-0.1 ( Guess H. )54.8 (All-cause mortality and vascular)]TJ
2.175 -1.25 Td
(events among patients with rheumatoid arthritis, osteoarthritis, or)Tj
T*
(no arthritis in the UK General Practice Research Database. )Tj
T*
[(J Rheumatol 2003;30:1)36.8 (196-202.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (W)79.9 (olfe F)79.7 (, Mitchell DM, Sibley JT)73.9 (, et al. )17.7 (The mortality of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis. )54.8 (Arthritis Rheum 1994;37:481-94.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Philben EF)79.7 (. Factors determining angiotensin-converting enzyme)]TJ
2.175 -1.25 Td
(inhibitor underutilization in heart failure in a community setting.)Tj
T*
(Clin Cardiol 1998;21:103-8.)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(1248)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:7)Tj
ET
0 0 0 0 k
/GS0 gs
104.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\7MiP\/#ikr7d(aYU(6$]h.?1o#l%HI22@;A$d/erN"C%U']Us+@puCsp59,j<
3IrCo[@fa^KqVp&ngsRML`H.6]5tupEt<%>+*#Y72gdccQamNV(fs+Wf?L8G)Ok_G
gR`.I11urdRYUUAhg$Z?Xd,%&^352#m>%m@a-e4&6`ch(ap.*#-G_qD?AgruD\H9en-.=D+-t!4Q=trB=ZqY[S@?j"
iWW@?YN[Y"lIecsU>>D=aD>qU0n]IPN%T"2R7-I,UOp_bfECd\Kg1U:)I3'Ch@V*s
Z1ush,+G0Eo>L:FV;RV;FMi)T%Xg(7$i4&[l_IZBpW>bO[;Ygq#RVVnX>1e!X9(Q#
nXZB2*7#>_3DS*RY@qdk3W1OUqE)l-I*%,RCo9Un:ad"bKgObm@2kRpfa[s5?8q?6
jkbFZhmQ@+iF`/Gq9^J~>
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
64 0 obj
<>
endobj
16 0 obj
<>
endobj
52 0 obj
<>
endobj
88 0 obj
<>
endobj
106 0 obj
<>
endobj
53 0 obj
<>
endobj
79 0 obj
<>stream
HtTkPWaqiGv7bT*aWwE@"=sd+ /Bn,V BsU6-Ƹ9M.[نǦjnթ[|_a,0H4;p
Cq*De:r|%xG?ǂgļ4f,lZ٢U($8S#d%ZIFm.:o.I+=/${b.rOɸl*zMF/w;JⶤUqzn}|F)UQK8;6|A*]p:1sJ.QR)u8M4QILKPq2>jFǩ<}R^V*>&6b
D`.blr[akU17Samhgu,ފu.uNb*KrӥҚK_\dY?cN+Jejfa쨵u,Y=6klrN^'Gv3=va;]ܾa)' ]t_\(H }AwNW2{
ttHt~F>C܈C!@,joYVVѤmZ
5,䬨!|(1Sy\L!O4}!APKI WXEZy?JpL)+0Av\
O{jJ:Gظp|!-3)4fڿ+ 3FDŘ,'ݐ^K fztK'+@LM.^sM{6#(% `r;]rx(3XSPuEۥ>E:!vL'>M4h$wS-{oTDLKu=
LY5kb 9ያm'>]wo T@>?E~ב `<
Ŕw\ ĄO:*#dE.!)33$ սOBn'k ]ߥHM>1kaۏf1l_;VA_)7߃6j|
JEEhw[êwyg6Cơ0fg]Z)نQukG(ZLk<dQ>";yT A@'
E ?gr6:H~0Whz~|Aգ,)a-> !F}D) z1!zz*e(C~z!=5aA-:fjjez,bU[Y)۴Vv6kcuX6gX2;x5'BWj'B!],ZFPa|LogA$'`uxGJELB
f2K>=WdzYg! c/W=ʪE@a;
;=r).zR#V(?hcõے?V o$Z[)=w %__KE)<*ͥyڍqFU6UJv/m)?>9^i,#y
J&(ËBᓕe3
rmȑ[h#܆9o[k" 9/h,nufld=av k]ϐ/Ժȉ!Gd0*J˯+F;#wl\\ʠ/.SqWQO&OQ4䇴(|??tw'~W!O|)$!2SXu q
j:%'֘@pD`+ Dj" dIIEZi,>N[eqٸ5'jLr"S/܆}?SP⦲S``aYF:2J&efg:$e#CR;W):"LE9l!-nkCwG5ufA|/8&^j希V=j:cg, (l!,de%@հ)(:TUGd,=ө{,_c~|߽wDRR!Յ+QK1;RSI]XqUWhoFgZmW2f2NZJMB=wB(VL@5gqd}nmEP/ǻ
dR,P{jς0iz9OӀ2?m)fya
GOa,8Q}gyLìԳnD{[1"3fXgq[^%_'dGY'\7 ѸPD$E))BQAE}`3uYsi!Cc?D=xK~k R/;ם}S$ϩR?FR0h~|cZ_Yvyb`yRQ)!n-<eGȬl]h2F7 0 -L[}2^uKg-y)0+&㩹T'QExtLxZ<->̄CvFb *sͫlSU)vKyD/H,H sTR+)1R5ʀD8'`o~cz
D ROAo3ScrNCs 2)
U~Y"[I^_v Y&{Mxõh
pm3,Ӛc?k`~cn$/Idb
Bܶ@ 56F AC[tX@&+@W Z} /)j0b`!NxcA!ƹd.YЉ|W
b$lfY9Jtݟ~)(&$w,YcĈ*]^bnlO*~|:}yO_q0v*F]uT:4uOaN9FA w
ACYQRim ͩsw}{d]K燇n+նhIjثLGop=8\)?I;F-Q%=Iߝ?%Ǩqp.)TS{'q%EL $iqnA}h)A\(
QOGiNxEn(7|9oX׳pEOE@D\}_ΔK'GHgbv(tdoMA6gtP,6#mh32ˣvPc@`7,X{#97~Cm') $Ber1xj*U&
QiјoԦǠc
.[D@3FFH!,1?pEty^ >`FS4r"67#1@kٽ w\ z&-/?mPhZBE-&"U:0
/k4m ,k`ӛmYJq`'A[5@|V]ǟo{@4$OUe賫`Vs ŕ:o\)\8._\u?w 4FT[J"b8{MXX",PZ*YQ7H
WrxrTT@ÜUt!Ya5i"o],y2Y#Vѱ˧P=oj}L /:N+guJ5| s nwlJ06J5SЍ%1DprZGRpc. ucm;X TV+]jɺb*Iߧ%rAt|pm`ӷC%_"ZGuu7\}~
uo=r,J#Ɖsi"A*rhb&k68v9"ٟFJ+
U;S;v RRdlWiTT&bXWMڨ'c#1Jc"b ٗ
030+˰
D
%شw.$͏s{}yyFYmV_5iԍ%.6%вg->h8K>OU6Ѝ~I"u[c7%JzC]V~zNOemq !F((<ڧ<7xM 鰖bC`>gu:я.s1|8>?CaJHbяɪҔ
:Uҹ;>N^v+]
՚%=I[;㠟/AF ~C*:b9 'cgR酱λ4X|`2@߷pR3EdXOtg¶mFX8`}
a۸(ETR;nE}0z; f?恌dGo.ȩ[w~4DZLe2lfNԝGuiKӗZV<8_Ҁ=7UɐruÄ`DM}SW:Lxg!kã7y yxV.ýH[@G'F?nrt<|>Z}{ڰ
0ͺxJk>+fW dYbX~m'8VY>A(@ 0_k>n_H^ͣ~Ӣo,u/yy*LEJa/?E bKZ4m$p}Ј}iX8rK(R+f˒?2[ٹro"+
4=
[yy<һ/PÇkHq
gl6ɮj\N/M!'7-хvxV\s6C